At Polaris, we’re dedicated to decoding the biological fingerprints of mental health to advance the discovery and development of tools and diagnostics for a range of conditions, including PTSD, depression, anxiety, ADHD, TBI, and substance use disorder. While we recap our annual milestones, we also welcome you to support, share, and shine a light on our mission, as it guides us into 2024 and beyond:

Polaris Genomics harnesses AI-powered genomics to define the biological underpinnings of mental health, develop objective diagnostics, and unlock novel therapeutics.

Here’s a glimpse at our top news in 2023, investments, partnerships, and studies on the horizon:

• We were awarded $1.25 million in funding from the Air Force through the AFWERX program, which will support our new PTSD study commencing in 2024: We are excited to kick off a large prospective trial in 2024 to support further development and FDA approval of PTS-ID™.
• We successfully filed a new international patent application for genetic biomarkers used in our PTS-ID™ test.
• Using our neuropsychiatric research and discovery panel, the ADAPT Panel™, we partnered with the University of South Dakota, the University of Maryland, and Defence Research and Development Canada on diagnostics work. We look forward to announcing new pharma partnerships on the horizon.
• Polaris Genomics continues to garner investments as it brings molecular diagnostics to mental health. The recent $2 million investment by Viking Global, Wavemaker 360, and TEDCO is being used toward expanding our platform. Read More.
• We joined the Johnson & Johnson Innovation ecosystem as part of JLABS @ Washington DC, and are actively leveraging strategic collaborations in this well-established ​​life science and healthcare incubator.

Don’t miss this: Visit our Insights blog for inspiring personal stories and impassioned interviews with various members of the Polaris team over the last year.